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assessing ARV drug resistance. Genotypic assays detect
specific point mutations in the HIV genome that are
associated with phenotypic resistance. These are most
often detected by direct sequencing of the protease (PR)
and reverse transcriptase (Rn genes following PCR
amplification. Plasma samples are recommended for
genotyping and in general a viral load of at least 1 000
copies/ml is required. These assays can detect up to 25010 of
resistant variants in mixtures of mutant and wild-type
genomes. However, it is becoming increasingly important
to be able to detect populations that occur at a lower
frequency, so-called minority populations, which can
rapidly become dominant once drug pressure is applied.
Genotypic testing is the most frequently used method as it
is rapid and less expensive than phenotyping. However, it
is an indirect measure of resistance and provides no
indication of the degree of phenotypic resistance to a given
drug or combination of drugs (cross-resistance). A
compendium of resistance mutations for currently used
ARVs is available on-line together with interpretation
algorithms (www.hivdb.stanford.edu/hivn, although
expert clinical opinion together with a detailed treatment
history is often required for accurate interpretations,
particularly for patients failing complex regimens.
Phenotypic assays measure the susceptibility of a virus to a
specific drug in a culture assay. In general an isolate able to
replicate in 5 - 10-fold higher concentrations of drug
would be considered to show phenotypic resistance. These
assays have been problematic in the past as they relied on
the ability to isolate HIV from individual patients.
Nowadays assays based on recombinant DNA technology
are used, where the gene regions encoding RT and PR are
amplified and inserted into a laboratory strain. These hybrid
viruses are grown in the presence of increasing
concentrations of various drugs and the levels of viral
replication monitored. These assays are time-consuming
and expensive but provide a more direct measure of
resistance as well as useful information on the levels of
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Genotypic and phenotypic assays are available for
ANTIRETROVlRAL DRUG RESISTANCE TESTING
Mother-ta-child transmission of HIV-l (MTCD remains a
major route of infection in South Africa, where 25% of
pregnant women are HIV-infected' and an estimated
70000- 80000 HIV-infected infants are born annually. The
risk of transmission is highest during labour and delivery,
and studies have demonstrated that antiretroviral (ARV)
treatment, initiated either antenatally or in the intrapartum
period, can result in significant reductions in transmission
of HIV-l from mother to infant. Widespread introduction
of these regimens to prevent MTCT in South Africa will have
a major impact on controlling perinatally acquired HIV
infection. The presence of ARV therapy can alter viral
ecology, and if the therapy allows ongoing viral replication,
drug-resistant variants may become selected as long as the
drug is administered. There has been some concern that the
use of ARV monotherapy for the prevention of MTCT,
including zidovudine (ZOV) or nevirapine (NVP) used alone,
could result in the development of drug resistance with
potential implications for perinatal transmission, the
choice of therapy for the HIV-infected infant and future
maternal therapeutic options. In the USA and other
developed countries, the oetection of ZDV or other
resistant variants has not been found to be associated with
an increased risk of MTCT' and, while perinatal transmission
of a resistant variant has been reported, this occurrence
appears to be infrequent and unusual.'~ In a substudy of
the Women and Infants Transmission Study Group (WITS),
univariate analysis showed that ZDV resistance was not
significantly associated with transmission, but when
adjusted for duration of ruptured membranes and total
Iymphocyte count, resistance mutations conferred an
increased risk of transmission.' However, these women
were more likely to have higher viral loads and lower CD4
counts and needed to be on ARV treatment for their own
health.
resistance and cross-resistance. Phenotypic resistance tests
are also used to determine whether previously unknown
treatment-associated mutations confer resistance. While
these assays are generally easier to interpret than assays
for genotypic resistance, the clinical significance of low
levels of phenotypic resistance remains uncertain.




The prevalence of ARV drug-resistant variants in therapy-
na"ive HIV-infected pregnant women varies geographically.
The prevalence will depend on background use of ARV
therapy within the population and the type of assay used
to measure resistance.' In the USA and Europe, where the
predominant HIV sub-type is B, rates of primary resistant
variants in the reverse transcriptase gene (which drugs like
ZDV, 3TC, ddl, d4T and nevirapine target) were between
1Q01o and 23%.' Resistance occurs in these populations
because ARVs have been in use for many years and is not
related to subtype. In South Africa, where the predominant
subtype is C, and where ARVs are not readily available for
widespread use, drug-resistant viruses do not appear to
be prevalent in HIV-infected pregnant women." The
prevalence of resistant variants in pregnant women will
vary depending on the population studied, i.e. whether or
not ARVs are in widespread use. In the USA, a study
confirming the efficacy of ZDV in preventing MTCT
(ACTG076 study), no high-level resistance to ZOV was
detected.' In contrast, among women who were receiving
ZOV for health reasons prior to 1994, any ZOV resistance
was detected among 25% of women, and high-level
resistance was detected in 1Q01o of the isolates. Vet there
have been a few perinatal transmissions in heavily treated
women.
Rapid development of resistance to 3TC has been reported
among HIV-infected adults who have received dual
nucleoside therapy without other agents. In a small study,
4 out of 5 women treated with ZOVj3TC in pregnancy had
the M184 V 3TC resistance mutation detected by delivery.'
Similarly, in a French cohort who had 3TC added to a ZOV
regimen at 32 weeks found an increase of the M184V
mutation from baseline (2% at baseline to 39% at 6 weeks
post partum)." Resistance has also been assessed in the
PETRA (Perinatal Transmission) study where ZOV and 3TC
were used. In PETRA arm A, where women received ZOV and
3TC antenatally for 4 weeks, during labour and delivery, and
post partum for 1 week, 2 women were found to have the
M184V; these 2 women did not transmit the virus to their
infants" Because of the profound reduction in
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transmission rate using this regimen, short-term treatment
with dual nucleoside therapy may be considered in
pregnant women for MTCT prophylaxis. In a study
conducted at the Chris Hani Baragwanath Hospital, where
women were randomised to receive 4 weeks of ZOV or 04T
or 001 or a combination of d4T and ddl, no resistance was
seen in HIV-infected infants at 6 weeks of age."
NON-NUCLEOSIDE REVERSE-TRANSCRI PTASE
INHIBITORS (NNRTls)
The only NNRTI that has been tested in MTCT so far is NVP.
Studies conducted in Uganda and in South Africa have
demonstrated that drug-resistant mutations were present
in maternal and infant viral sequences after NVP was
administered as part of an MTCT regimen.'''' In Uganda,
where a single dose of NVP was administered to HIV-
infected women, these mutations were not associated with
failure to prevent MTCT,' i.e. they did not compromise the
efficacy of NVP in preventing MTCT. This study showed that
the rate of development of NVP resistance was
approximately 18% in mothers 6 weeks after exposure,
and that these resistant mutations were undetectable 18
months after delivery. In the South African Intrapartum
Nevirapine Trial, selection of resistance mutations was
determined in a trial of two doses of NVP compared with
7 days of zidovudinejlamivudine (ZOVj3TC) for the
prevention of MTCT of HIV. HIV genotyping was performed
on plasma samples collected 4 - 6 weeks postpartum from
women receiving NVP and ZOV!3TC and HIV-l-infected
infants born to mothers who had received NVP. HIV-1
genotyping was then repeated on samples taken 9 -12
months post portum. No ZOV or 3TC mutations were
detected in the women who received the multiple-dose
ZOVj3TC regimen. NVP resistance mutations were detected
in 74 [67%) of the 111 women who had received 2 doses of
NVP. The predominant NVP mutations found were K103N
(62%) and V181C (45%). Studies of the infected infants
(4 - 6 weeks of age) demonstrated NVP mutations in 53'\'0.
The predominant mutation was V181C, which was present
in 53% of the infected infants. Paired data from 26
mother-infant pairs suggested that in a few instances
NVP-resistant virus may have been transmitted through
breast-feeding. However, the presence of these mutations
is unlikely to have been the reason for infection in the child,
as in the absence of NVP these variants have no selective
advantage but merely refiect what was present in the
mother at the time of transmission. Long-term follow-up
samples showed that in women with NVP resistance
mutations detected at 4 - 6 weeks, most virus had reverted
to wild type by 13 months. In summary, the use of a 2-dose
maternal regimen for preventing MTCT is associated with
an increased frequency of resistant variants and the results
from the SAINT data favour the use of single-dose NVP.
Tm SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE
-----------OCTOBER 2002
RESISTANCE TESTING RECOMMENDATIONS
The International AIDS Society-USA Panel and
Euroguidelines Group for HIV resistance recommend that
all pregnant women with detectable HIV RNA levels have
resistance testing performed, even if they are
antiretroviral-na"ive. This is to maximise the response to
ARVs during and after pregnancy and to aid in the choice
of antiretroviral therapy should the infant be HIV-infected.
However, no data show that routine resistance testing
decreases MTCT or improves maternal outcome, and until
further data become available, resistance testing for HIV-
infected pregnant women should be the same as for non-
pregnant adults. The situation may be different in
developing countries where single-dose NVP is likely to be
widely used. Table I is a guide for resistance testing in HIV-
infected pregnant women.
TABLE I. INDICATIONS FOR RESISTANCE TlESTlNG IN
HIV-INFECTED PREGNANT WOMEN
• Acute infection/seroconversion
• Virological failure with persistently detectable HIV RNA
levels while receiving antenatal therapy, or sub-optima! viral
suppression after initiation of highly active antiretroviral
therapy
• Those with a likelihood of having resistant virus based on
the community prevalence of resistant virus, e.g. known
drug resistance in sexual partner
• Previous exposure to single-dose NVP?
HIV RESISTANCE ASSAYS IN PEDlATRICS
In HIV-infected adults, resistance assays may prove useful
in guiding initial therapy and in changing failing regimens,
but their value in children has not been established and
expert clinical interpretation is required. Standardisation of
assays used will be necessary before these assays can be
incorporated into the clinical care of children. If resistance
testing is performed in infants, these tests should be done
while the infant is being exposed to the ARV therapy. In the
absence of drug pressure, wild-type virus will dominate
and may mask the presence of resistant virus.
As viral replication is higher in infants than in adults, and
this puts them at increased risk of developing ARV
resistance. Indeed, in HIVNET 012 children had a higher
frequency of NVP resistance mutations than their mothers.
Furthermore, mutational patterns to NVP often differed
between infants and their mothers, suggesting that other
factors might impact on the development of resistance
mutations in children, such as the immature immune
response. Further studies on the evolution of ARV in
children are warranted.
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THE CHOICE OF REGIMENS FOR HIV-INFECTED
INFANTS EXPOSED TO MTCT REGIMENS
The use of ZDV and NVP as single agents to prevent MTCT
is recommended. The management of HIV infection in
infants is rapidly evolving and increasingly complex. Where
possible, ARV therapy in an infant under' 2 months of age
should be initiated in consultation with a specialist in the
treatment and management of HIV infection. The choice of
ARV regimens for the initiation of treatment should take
into account the limitation of future treatment options, as
well as the presence or future development of ARV
resistance. There are potential problems with early
initiation of therapy, including short-term and long-term
side-effects, inadequate data on drug dosing,
pharmacokinetics and safety. The initial ARV regimen
chosen for HIV-infected infants could theoretically be
infiuenced by the ARV regimen the mother was exposed to
during pregnancy. If she received ARV treatment during
pregnancy, either to reduce MTCT or for her own disease,
there is a possibility that she may transmit resistant virus
to her baby should he or she also become infected. This is
a particular problem when NVP or 3TC has been used as
part of a non-suppressive regimen, as resistance to these
drugs can be induced rapidly by a single-point mutation.
Data from the USA do not suggest that the ARV regimen
for the newly diagnosed HIV-infected child should
routinely be chosen on the basis of the maternal regimen.
If maternal ARV drug resistance is documented or
suspected, resistance testing of infant viral isolates may be
considered in order for the clinician to assist in the choice
of the initial ARV regimen. It is not known whether ARV
choices for infants who have been exposed to non-
suppressive ARV regimens used to prevent MTCT should be
modified. The efficacy of first-line highly active
antiretroviral therapy (HAART) treatment regimens
containing NVP or 3TC for infants who are infected despite
prophylaxis containing these drugs requires further
research. In the meantime, prior administration of short-
course ZDV/3TC should not preclude use of these drugs as
part of combination ARV drug regimens for treatment of
HIV-infected children, particularly those initiating therapy
at 12 months of age or older (at which time wild-type virus
is likely to predominate). There are no data on the efficacy
of NVP used in combination with other ARVs in the
treatment of HIV-infected infants after having received
NVP as part of preventing MTCT. Until such data become
available, it may be advisable to avoid using NVP or
efavirenz in the initial ARV regimen. If ZDV monotherapy
was used in MTCT, available data support the use of ZDV as
part of combination therapy in HIV-infected infants.
THE MANAGEMENT OF HIV INFECTION IN INFANTS
, AND CHILDREN EXPOSED TO MTCT REGIMENS
Once HIV infection has been confirmed in the infant, any
ARV therapy that has been used for prophylaxis for MTCT
should be stopped. In general, the local South African
guidelines do not recommend treating infants under 3
months of age with ARV therapy unless they fulfil the
indication for starting therapy [clinical category Bor C. or
CD40f0 < 200/0). If the clinician is considering resistance
testing, this should be undertaken while the infant is still
receiving the prophylaxis to assess the prevalence of
resistant mutations and to provide information that will
guide the clinician in his/her choice of the initial regimen.
If the child or infant is not on any prophylaxis, there is no
value in doing resistance testing, and a detailed maternal
drug history will aid the clinician in the choice of the initial
regimen.
CONCLUSION
Perinatally acquired HIV is a potentially preventable disease
and the introduction of interventions to prevent MTCT in
South Africa will help control paediatric HIV Further
research is required into the prevalence and significance of
ARV drug resistance in MTCT. Although evaluations of MTCT
trials have demonstrated the emergence of NVP-specific
genotypic mutations in treatment-na'ive HIV-infected
women after a single dose regimen, the ability to detect
these mutations decreases over time, and they are
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undetectable 18 months post portum. There are currently
no data to suggest that a single dose of NVP used for the
prevention of MTCT will affect the efficacy of a NVP-
containing treatment regimen for HIV-infected children.
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